Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment.
Open Access
- 1 August 1989
- Vol. 30 (8) , 1110-1115
- https://doi.org/10.1136/gut.30.8.1110
Abstract
We have applied a specific and accurate high pressure liquid chromatographic technique to determine fasting serum glycine and taurine conjugates of individual bile acids in patients with primary biliary cirrhosis before and during ursodeoxycholic acid therapy. The study was carried out in nine patients in whom the diagnosis of primary biliary cirrhosis was established according to accepted criteria. After one year of UDCA therapy liver function tests significantly improved. Total serum bile acid concentration did not change significantly (29.2 (31.5) v 28.3 (26.4) microM). Total UDCA (1.7 (2.2) v 13.3 (14.5) microM) and glyco UDCA (0.8 (1.6) v 10.9 (11.4 microM) but not tauro UDCA levels increased significantly (p less than 0.01); UDCA (7.7 (12.6) v 40.2 (12.7)%) became the major species of the circulating bile acids. Primary bile acids (23 (28.3) v 11.2 (10.5) and their glycoconjugates fell significantly (p less than 0.01). There were no significant changes in the concentrations of conjugates of the secondary bile acids (4.5 (3.8) v 3.9 (3.0]. Our study shows that oral administration of UDCA to patients with primary biliary cirrhosis induced marked changes in the circulating pool of endogenous bile acids together with improvement in liver function test values. The data also suggest that the beneficial effect of longterm administration of UDCA in these patients might be mediated through changes in the circulating primary bile acids and UDCA rather than through changes in the circulating secondary bile acids, deoxycholate and lithocholate.This publication has 17 references indexed in Scilit:
- IS URSODEOXYCHOLIC ACID AN EFFECTIVE TREATMENT FOR PRIMARY BILIARY CIRRHOSIS?The Lancet, 1987
- Ursodeoxycholic acid treatment in humans: effects on plasma and biliary lipid metabolism with special reference to very low density lipoprotein triglyceride and bile acid kinetics*European Journal of Clinical Investigation, 1986
- Extraction and fractionation of bile acids and their conjugates using pre-packed microparticulate silica cartridges (sep-pak sil® and bond-elut® C18)Journal of Chromatography B: Biomedical Sciences and Applications, 1985
- Influence of Hydroxylation and Conjugation of Bile Salts on Their Membrane-Damaging Properties-Studies on Isolated Hepatocytes and Lipid Membrane Vesicles†Hepatology, 1984
- Ion-pair extraction of bile acids with Lipidex gelAnalytical Biochemistry, 1983
- ABO-INCOMPATIBLE BONE-MARROW TRANSPLANTATION: REMOVAL OF RED BLOOD CELLS FROM DONOR MARROW AVOIDING RECIPIENT ANTIBODY DEPLETIONThe Lancet, 1982
- Ursodeoxycholic Acid: A Safe and Effective Agent for Dissolving Cholesterol GallstonesAnnals of Internal Medicine, 1982
- Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis part IIDigestive Diseases and Sciences, 1982
- Choleretic and cholestatic effects of infused bile salts in the ratCellular and Molecular Life Sciences, 1979
- Effect of ursodeoxycholic acid administration on biliary lipid composition and bile acid kinetics in cholesterol gallstone patientsDigestive Diseases and Sciences, 1979